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Abstract
Aims To evaluate whether peripheral circulatory ‘remodelling’ as measured by changes in vascular compliance and in
markers of nitric oxide signalling contributes to patient response to cardiac resynchronization therapy (CRT).
Methods and results Effects of CRT were evaluated in 33 patients pre-procedure and 6 months post-procedure. Peak oxygen
consumption, 6 min walk distance, New York Heart Association class, and quality of life score were evaluated. Augmentation
index and its interactions with nitric oxide (NO) were evaluated by applanation tonometry. Platelet NO responsiveness and
content of thioredoxin-interacting protein were assessed. Plasma concentrations of N-terminal proBNP, asymmetric and
symmetric dimethylarginine (SDMA), high sensitivity C-reactive protein, catecholamines, and matrix metalloproteinases-2
and -9 were assessed. Despite signiﬁcant improvement in 6 min walk distance (P = 0.005), New York Heart Association class
(P < 0.001), quality of life (P = 0.001), and all echocardiographic parameters post-CRT, there were no signiﬁcant changes in
augmentation index measurements, thioredoxin-interacting protein content, and platelet NO response. Signiﬁcant falls in N-
terminal proBNP (P = 0.008) and SDMA (P = 0.013; independent of renal function) occurred. Falls in SDMA predicted reduction
in high-sensitivity C-reactive protein (P = 0.04) and increases in peak oxygen consumption (P = 0.04). There were no correla-
tions between changes in echocardiographic parameters and those in vascular function.
Conclusions These data suggest that the beneﬁcial effects of CRT over 6 months are independent of any change in peripheral
NO-related signalling. However, there is evidence that suppression of inﬂammation occurs, and its magnitude predicts extent of
clinical improvement.
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resynchronisation therapy (CRT); Nitric oxide (NO) signalling; Left ventricular dyssynchrony
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Introduction
Over the last two decades, as a result of several landmark
trials demonstrating mortality and morbidity beneﬁts with
cardiac resynchronization therapy (CRT) with or without
deﬁbrillation insertion,1–3 CRT has become a standard of care
in select patients with systolic heart failure and concomitant
left ventricular dyssynchrony. Substantial limitations of CRT
include not only the 30–40% of recipients classiﬁed as ‘non-
responders’2 but also signiﬁcant heterogeneity in the com-
monly used criteria of response and poor agreement between
these different clinical and echocardiographic parameters of
response.4 There has been considerable interest in under-
standing the mechanisms underlying beneﬁts associated with
OR IG INAL RESEARCH ART ICLE
© 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
ESC HEART FAILURE
ESC Heart Failure (2017)
Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ehf2.12211
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any me-
dium, provided the original work is properly cited and is not used for commercial purposes.
CRT and speciﬁcally whether these arise purely from mechan-
ical correction of dyssynchrony. Of particular interest is the pu-
tative effect of CRT on peripheral vascular function. Two small
studies have shown consistent improvement in microvascular
cutaneous reactive hyperaemia post-CRT insertion,5,6 while
studies of the effects of CRT on large conduit vessels utilizing
ﬂow-mediated [i.e. nitric oxide (NO)-dependent] dilatation
(FMD) have shown conﬂicting results.7–9 In this present study,
we sought to evaluate the effect of CRT on peripheral vascular
function and associated markers of inﬂammation, as well as
vascular and platelet NO signalling, we also examined the
effects of CRT on parameters of inﬂammatory and neurohu-
moral activation.
Objectives of the study were as follows:
(1) To evaluate whether the optimal outcome post-CRT is
engendered not only by reversal of left ventricular sys-
tolic dysfunction but also by amelioration of peripheral
circulatory dysfunction.
(2) To evaluate the effects of CRT on neurohumoral
activation.
Methods
Thirty-three patients with conventional indications for CRT
were prospectively evaluated before and 6 months after CRT
insertion. Clinical characteristics were noted, including New
York Heart Association functional class status, and quality of
life was evaluated using the standard (and well-validated)
Minnesota Living with Heart Failure Questionnaire.
Exercise capacity was evaluated both by 6minwalk distance
and by cardiopulmonary exercise testing.
Six minute walk distance
The protocol for the 6min walk distance has been described.10
This test was performed indoors in a dedicated and marked
hallway that is 30 m long with a hard ﬂoor. Cones were used
to delineate the turn-around points. The procedure was duly
explained, and patients were asked to walk as far as possible
and as fast as they could for a timed period of 6min. They were
allowed to slow down, to rest or to lean against the wall if
necessary, at their own discretion, and to resume walking
again at their possible fastest pace. Running or jogging was
not allowed. The test was terminated if a patient developed
chest pain, became unduly dyspnoeic, or looked ashen with
signiﬁcant diaphoresis. If any patient ordinarily mobilized with
a walking aid, he or she was allowed to use the same during
the test. The maximum distance walked at 6 min was recorded
for each patient.
Cardiopulmonary exercise testing
Cardiopulmonary exercise testing was performed according to
established guidelines.11 Brieﬂy, a bicycle ergometer (Model:
ergoline/100/200 GmbH, Germany) and linked to ExpAir
Medisoft S.A Belgique 1.31.02 software were utilized in all
cases. Before performing each test, the equipment was
calibrated both for airﬂow and volume, including low and high
ﬂows (with calculated volumes within ±3%) using a 3 L syringe
and also for gases with carbon dioxide set at 4% and oxygen at
20%. A semi-automated progressive incremental (ramp)
protocol in which the pre-test was set at 0 W while the
workload started from 10 W and increased by 10 W every
minute was used. Patients pedalled for a minute on the
pre-test setting of 0 W before loading commenced. They
were encouraged to exercise as long as possible, ideally for
up to 8 to 12 min, and especially aiming to achieve a
respiratory exchange ratio of 1 and above, with cycling rate
kept at 60–70 revolutions per minute. Volitional exhaustion
was the usual endpoint although exercise was terminated
if a patient developed chest pain, acute ischaemic changes
on the electrocardiogram, or hypotension. After unloading,
the patient pedalled for a further 1 min. Measurements
of oxygen consumption (VO2), carbon dioxide output,
ventilator equivalent, and respiratory exchange ratio were
automatically acquired and ﬁnally averaged and displayed at
10 s interval. The highest reading of the three last averages
at peak exercise was chosen as the peak oxygen consumption
(VO2 max).
Echocardiographic measurements
All echocardiographic measurements were performed ac-
cording to the American Society of Echocardiography and
the European Association of Cardiovascular Imaging guide-
lines.12 A Phillips echocardiogram machine model iE33,
2009, Bothell WA, 98041 USA was used for image acquisition,
and analyses were performed using Echopac Software Only
BT 11 Version 113, 2013 General Electric Co. M-mode echo-
cardiographic analysis was used to assess left ventricular
interventricular dyssynchrony. Septal to posterior wall delay
was calculated as the time difference between the onset of
the QRS to that of the peak of deformation of the inter-
ventricular septum and the left ventricular posterior. Al-
though extent of dyssynchrony was analysed as a continuum,
septal to posterior wall delay of 130 ms or more was
considered diagnostic of clinically signiﬁcant of intraventricu-
lar mechanical dyssynchrony.13 Left ventricular volumes
including end-diastolic, end-systolic, and stroke volumes
were measured in two dimensions and ejection fraction
calculated by the modiﬁed Simpson’s method in biplane
using 2D images.
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Vascular endothelial function
Vascular endothelial function was assessed by changes in
augmentation index (AIX) using radial artery applanation
tonometry as previously described.14 Brieﬂy, patients were
ﬁrst rested in a supine position for 30 min. Using a commer-
cially available pulse waveform analyser, the SphygmoCor
system (AtCor Medical, Sydney, Australia, model CvMS V9),
baseline AIX was computed as the average of three readings.
Sublingual glycerine trinitrate (GTN 300 μg) was administered
and AIX remeasured every 5 min for 20 min. The difference
between the lowest value of AIX with GTN and the baseline
AIX (that is, the maximum fall in AIX with GTN) was utilized
as a measure of endothelium-independent NO signalling.
Subsequently, 400 μg of inhaled salbutamol was adminis-
tered, and measurements were repeated every 5 min for
20 min. The difference between the lowest AIX with
salbutamol and the baseline (the maximum fall in AIX with
salbutamol) represents a measure of endothelium-
dependent NO signalling.15 Using the acquired radial artery
waveform, a validated, generalized transfer function was
used to generate the corresponding central aortic pressure
waveform from which AIX values were calculated. All
measurements were indexed to a heart rate of 75 b.p.m.,
and only high ﬁdelity tracings were used.
Platelet expression of thioredoxin-interacting
protein
Platelet expression of thioredoxin-interacting protein (TXNIP)
was quantiﬁed by immunoﬂuorescence as previously
described.16 Brieﬂy, blood was collected in ethylenediamine-
tetraacetic acid (EDTA) tubes and spun at 250 g for 10 min
at room temperature. Slides were smeared, air-dried, and
ﬁxed with 4% paraformaldehyde and stored in 70°C freezer,
and immunoﬂuorescence staining performed within
6 months.
For immunoﬂuorescence staining, the slides were allowed
to warm to room temperature and then washed three times
in phosphate-buffered saline (PBS) for 5 min per wash. A
100 μL of diluted goat’s serum 1:5 with PBS (as a blocking
solution) was added and incubated at room temperature
for 30 min. Primary antibody was prepared by diluting rabbit
anti-Vitamin D3 Up-regulated Protein (VDUP) TXNIP,
(Invitrogen Corporation, Carlsbad, CA, USA) with 1% (w/v) bo-
vine serum albumin in PBS in 1:50 ratio. The blocking solution
was discarded without washing the slides, and then, 100 μL
of the primary antibody was added and incubated overnight
at 2–4°C. The primary antibody was discarded the next day,
and the slides were washed three times in PBS for 5 min
per wash. Two conjugated 2° antibodies: dilute
phycoerythrin-labelled CD41 antibody (Becton, Dickinson
and Company, USA), in 1:50 with PBS, serving as a platelet
marker, and dilute ﬂuorescein isothiocyanate-labelled anti-
rabbit polyclonal antibody (Becton, Dickinson and Company,
USA), in 1:100 with PBS were prepared while shielded from
light. A 100 μL of each of the 2° antibodies was added to
the slide and incubated at room temperature for 60 min.
The slides were again washed three times in PBS for 5 min
per wash, dried with lens tissue, and one drop of Dako ﬂuo-
rescent mounting medium was added, covered with a slip,
and allowed to sit at room temperature for 10 min. Image ac-
quisition was performed with Carl Zeiss Microscope,
Germany, using ×400 magniﬁcation, multichannel for rhoda-
mine and green ﬂuorescent protein and exposure time set
at 5000 ms. The intensities of TXNIP staining for each platelet
were obtained utilizing image analysis software (AxioVision
40 version 4.8.2, Carl Zeiss Microscopy, Germany)
Subsequent analysis or counting was performed by ran-
domly identifying 100 platelets per slide and average TXNIP
obtained.
Asymmetric dimethylarginine and symmetric
dimethylarginine
For asymmetric dimethylarginine (ADMA) and symmetric
dimethylarginine (SDMA) concentration estimation in
plasma, 10 mL of blood was collected in heparinized tubes
and immediately put in ice, before centrifugation at 4°C at
1800 g for 15 min. Plasma was collected in Eppendorf tubes
and stored at 70°C until analysed. Plasma ADMA and
SDMA concentrations were determined by high perfor-
mance liquid chromatography, as described previously.17
Brieﬂy, this involved extraction, derivatization with
ﬂuorescent derivatizing reagent (AccQ-Fluor™), and
chromatography.
Matrix metalloproteinase-2 and matrix
metalloproteinase-9
Matrix metalloproteinase-2 was estimated from blood sam-
ples collected in EDTA tubes, while matrix metalloprotein-
ase-9 was estimated from blood samples collected in
heparinized tubes. For both, collected blood was immedi-
ately put in ice and was centrifuged for 15 min at 1800 g
at 4°C within 30 min of collection. Platelet-poor plasma
was collected and stored at 70°C until analysed. Assays
were performed with R&D Quantikine quantitative sandwich
enzyme-linked immunosorbent assay (ELISA) kits (R&D
Systems Ltd, Minneapolis USA) according to the manufac-
turer’s instructions. Plasma concentrations of matrix
metalloproteinase-2 and matrix metalloproteinase-9 were
determined by ELISA (R&D Systems Ltd) according to manu-
facturer’s instructions.
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Platelet aggregometry test; responsiveness to
nitric oxide
Platelet response to NO was assessed in vitro in whole blood
using a 4-channel impedance aggregometer (Chrono-Log
Corporation, model 700) according to a previously described
protocol, which required temporary interruption of therapy with
P2Y12 receptor antagonists.
18 Brieﬂy, 9 mL of blood was
collected into plastic tubes containing 1mL of acid citrate antico-
agulant. The blood was allowed to stand at room temperature
for 20 min before testing. A 500 μL of normal saline was pre-
warmed to 37°C in a 4-channel impedance aggregometer after
which 450 μL of whole blood was added to the saline and both
pre-warmed for 5 min. All tests were run at 37°C and a stirring
speed of 900 rpm. Platelet aggregation was induced with aden-
osine 50-diphosphate (ADP) (2.5 μM), and responses were mea-
sured as an increase in impedance (in Ohms), at 7 min. When
NO donor sodium nitroprusside (10 μM) was added to samples
1 min before adenosine 50-diphosphate, the resultant inhibition
of aggregation was evaluated as a percentage relative to control.
N-terminal proBNP levels
These were analysed by the South Australia Pathology labora-
tory at the Queen Elizabeth Hospital. Samples were collected
in heparinized tubes and analysed for N-Terminal proBNP with
the Elecsys proBNP system (Roche diagnostics GmbH,
Sandhofer Strasse 116, D-68305 Mannheim). The Sandwich
principle was used: this involves a ﬁrst incubation with a
biotinylated monoclonal NT-proBNP-speciﬁc antibody and a
monoclonal NT-proBNP-speciﬁc antibody labelled with a
ruthenium complex. A second incubation was performed with
the addition of streptavidin-coated microparticles, and the
microparticles were subsequently captured on the surface of
the electrode magnetically. A photomultiplier ﬁnally measured
the chemiluminescent emission induced by application of
voltage to the electrode.
Plasma metanephrine and normetanephrine
Analyses for catecholamine metabolites were performed with
fresh samples collected in K3EDTA bottles and analysed
utilizing liquid chromatography-tandem spectrometry. The
upper limits of the normal ranges for plasma concentrations
were <500 pmol/L for free metanephrine and <900 pmol/L
for free normetanephrine.
High sensitivity C-reactive protein
Samples were collected in K3EDTA bottles and analysed by the
immuno-turbidimetric quantiﬁcation method on Beckman
Coulter AU analysers (Beckman Coulter, Inc., Brea, CA, USA) ac-
cording to the manufacturer’s recommendations.
Ethics approval
The study complies with the Declaration of Helsinki, and
approval for the study was granted by the Ethics and Human
Research Committee of The Queen Elizabeth Hospital. All
participants provided prior written informed consent.
Statistical analyses
The power of the study was calculated on the basis of vari-
ability in responsiveness of AIX to salbutamol and was approx-
imately 80% to detect a 5% variation in response at P < 0.05.
All data are expressed as mean ± standard deviation unless
stated otherwise. The effects of cardiac resynchronization
therapy on clinical, biochemical, endothelial, and echocardio-
graphic parameters were assessed using paired t-test for
normally distributed variables and Wilcoxon matched-pairs
signed-rank test for non-parametric data. Each patient served
as his/her control. Interactions between changes in left ven-
tricular contractility and endothelial functions as well as the
interactions between changes in function and neurohumoral
parameters were correlated using Pearson correlation coefﬁ-
cients for normally distributed data and Spearman correlation
for non-parametric data. Relationship between categorical
changes in SDMA and changes in high-sensitivity C-reactive
protein concentrations and in VO2 max were evaluated by
non-paired t-tests. A two-tailed P value< 0.05 was considered
statistically signiﬁcant.
All data were analysed with Prism 6 for Mac OS X version
6.0h October 2015.
Results
The baseline characteristics of patients are listed in Tables 1
and 2. The mean QRS duration was 158.7 ± 23.6 ms. Approx-
imately half of the patients had an ischaemic aetiology of
heart failure, and the majority were in New York Heart
Association functional class III–IV pre-CRT implantation. All
patients were also extensively treated for heart failure, and
the majority were receiving β-adrenoceptor antagonists.
One patient died 2 months after CRT insertion, while three
patients declined the 6 month follow-up visit. Among the
whole cohort, there was signiﬁcant improvement post-CRT in
all echocardiographic parameters and in all clinical parameters,
with the exception of VO2 max, as shown in Figures 1 and 2
and Table 3. There was no signiﬁcant change overall in vascular
and platelet functions except for a statistically signiﬁcant
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reduction in plasma concentrations of SDMA (paired t-test,
P = 0.013).
As shown in Figure 3A–C, although a statistically signiﬁcant
inverse correlation existed at baseline between estimated glo-
merular ﬁltration rate and SDMA concentration, at 6 months,
signiﬁcant decreases in plasma levels of SDMA had occurred
without any change in estimated glomerular ﬁltration rate. It
is therefore unlikely that changes in renal function had
contributed to the observed fall in SDMA levels. A categorical
reduction in SDMA concentrations was predictive of both a
reduction in high-sensitivity C-reactive protein concentrations
(P = 0.04: Figure 3D) and an increase in VO2 max (P = 0.04:
Figure 3E). With regard to neurohumoral and inﬂammatory
activation, there was a statistically signiﬁcant reduction in
plasma levels of NT-proBNP (paired t-test, P = 0.008) but no
signiﬁcant change in any other marker of NO signalling or of
inﬂammatory activation. It must be noted, however, that in
the absence of signiﬁcant changes, effects of both salbutamol
and GTN on AIX tended to increase (by about 20%). On univar-
iate analysis, there was no signiﬁcant correlation between
change at 6 months in left ventricular end-systolic volume
and changes at 6 months in baseline AIX, GTN-mediated fall
in AIX, salbutamol-mediated fall in AIX, or with platelet NO
response.
Discussion
In this study, the ﬁrst point to be noted is perhaps the fact
that the cohort on the whole ‘responded’ to CRT, in the sense
that there was signiﬁcant improvement in parameters of left
ventricular ejection fraction, as well as signiﬁcant
improvement in symptomatic status as shown in Table 3.
Therefore, we have a cohort in whom there was effective me-
chanical cardiac resynchronization; otherwise, it would have
been futile for us to proceed with the pursuit of understand-
ing of any further mechanistic effect of CRT. The lack of statis-
tically signiﬁcant improvement in VO2 max was similar to the
results of some previously reported CRT studies19,20 although
CRT has also been shown to improve VO2 max.
2 In addition,
there was a signiﬁcant reduction in the plasma concentrations
of N-terminal proBNP, a similar ﬁnding to the CARE-HF trial.2
In this regard, a post hoc analysis of the MADIT-CRT trial21
found that reduction in BNP following CRT was associated
Table 1 Baseline characteristics of patients
Age (years) 71.2 ± 9.7
Female, n (%) 10 (30.3)
Weight (kg) 87.1 ± 18.6
Height (cm) 172.5 ± 8.1
BMI (kg/m2) 29.3 ± 6.1
Ischaemic aetiology of CHF, n (%) 17 (52)
History of current/past smoking, n (%) 19 (57.6)
NYHA class
• I, n (%) 3 (9)
• II, n (%) 7 (21)
• III, n (%) 19 (58)
• IV, n (%) 4 (12)
Comorbidities
• Hypertension, n (%) 21 (64)
• Diabetes, n (%) 14 (42)
• COPD, n (%) 4 (12)
• Atrial ﬁbrillation, n (%) 5 (15)
Medications
• ACE inhibitor 22 (67)
• Angiotensin receptor blocker 8 (24)
• β-adrenoceptor blocker 25 (76)
• Aldosterone Antagonist 18 (55)
• Digoxin 9 (27)
• Frusemide 24 (73)
• Statin 18 (55)
• Aspirin 17 (52)
• Clopidogrel 7 (21)
• Perhexiline 5 (15)
Clinical assessment
Systolic BP (mmHg) 126.4 ± 17.1
Diastolic BP (mmHg) 71.2 ± 9.2
Heart rate (b.p.m.) 69 ± 13.6
6MWD (m) 321.74 ± 104.62
VO2 max (mL/min/kg) 13.8 ± 4.7
QOL score 41.9 ± 25.6
Biochemistry
NT-proBNP (ng/L) 1814.0 (1091–3073)
eGFR (mL/min/1.73 m2) 56.4 ± 22.2
Plasma metanephrine (pmol/L) 252.1 ± 158.3
Plasma normetanephrine (pmol/L) 996.5 ± 396.2
Plasma MMP-2 (ng/mL) 217.5 ± 51.2
Plasma MMP-9 (ng/mL) 27.7 ± 9.1
high-sensitivity C-reactive protein (mg/L) 2.4 (1.4–6.1)
Ventricular function
LVESV (mL) 137.4 ± 55.3
LVEDV (mL) 192.8 ± 67.4
EF (%) 29.8 ± 6.1
SPWD (ms) 120.0 ± 195.0
IVMD (ms) 43.9 ± 44.0
6MWD, 6 min walk distance; ACE, angiotensin-converting enzyme;
BMI, body mass index; BP, blood pressure; CHF, chronic heart
failure; COPD, chronic obstructive pulmonary disease; CRT, cardiac
resynchronization therapy; EF, ejection fraction; eGFR, estimated
glomerular ﬁltration rate; IVMD, interventricular mechanical delay;
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular
end-systolic volume; MMP, matrix metalloproteinase; NT-proBNP,
N terminal proBNP; NYHA, New York Heart Association; QOL,
quality of life; SPWD, septal to posterior wall delay; VO2 max, peak
oxygen consumption during exercise.
Normally distributed data are mean ± SD; skewed data are
expressed as median values and interquartile values.
Table 2 Endothelial function/no signalling pre-CRT
Baseline AIX (%) 19.9 ± 7.8
GTN AIX change (%) 13.9 ± 10.0
Salbutamol AIX change (%) 11.3 ± 10.2
ADMA (μM) 0.6 ± 0.07
SDMA (μM) 0.73 (0.60–1.0)
Platelet SNP response (%) 33.9 ± 26.5
Platelet TXNIP (AU) 136.9 ± 111.2
ADMA, asymmetric dimethyl arginine; AIX, augmentation index;
CRT, cardiac resynchronization therapy; GTN, glycerine trinitrate;
SDMA, symmetric dimethyl arginine; SNP, sodium nitroprusside;
TXNIP, thioredoxin-interacting protein.
Normally distributed data are mean ± SD; skewed data are
expressed as median values and interquartile values.
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with signiﬁcant decrease in hospitalized heart failure and
mortality.
In spite of these salutary effects of CRT in our cohort, there
was no signiﬁcant change in conventional markers of periph-
eral vascular endothelial function as assessed by AIX with
radial artery applanation tonometry. Speciﬁcally, there were
no signiﬁcant changes either in baseline AIX or in
endothelium-independent and endothelial-dependent AIX, as
assessed with GTN and salbutamol, respectively. A potential
confounder to this apparent lack of effect on vascular
Figure 2 Effects of cardiac resynchronization therapy (CRT) on echocardiographic parameters in individual patients. (A) Left ventricular (LV) ejection
fraction. (B) Left ventricular end-systolic volume (LVESV). (C) Septal to posterior wall delay (SPWD). (D) Interventricular mechanical delay (IVMD). All
analyses were performed via paired t-test.
Figure 1 Effects of cardiac resynchronization therapy (CRT) on clinical parameters in individual patient. (A) New York Heart Association (NYHA)
functional class (n = 29: this is partially obscured graphically by identical changes in 20 patients). (B) 6 min walk distance (6MWD). (C) Peak oxygen
consumption (VO2 max). (D) Quality of life (QOL) score. All analyses were performed via paired t-tests.
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Figure 3 Implications of changes in plasma symmetric dimethyl arginine (SDMA) concentrations regarding renal excretion of SDMA, and variations in
high-sensitivity C-reactive protein concentrations and peak oxygen consumption (VO2 max) post-cardiac resynchronization therapy (CRT). (A) Correla-
tion between baseline estimated glomerular ﬁltration rate (eGFR) and SDMA concentrations(r = 0.80, P < 0.001). (B) Changes in eGFR post-CRT in
individual patients (P = NS). (C) Changes in SDMA concentrations post-CRT in individual patients (P = 0.013). (D) Changes in high-sensitivity C-reactive
protein concentrations (P = 0.04). (E) Changes in VO2 max values (P = 0.04).
Table 3 Effects of cardiac resynchronization therapy: analyses are limited to patients in whom 6 months data post-CRT were available
Parameters Pre-CRT Post-CRT P-value
Clinical
NYHA 2.7 (0.8) 1.9 (0.7) <0.001
VO2 max (mL/min/kg) 13.8 (4.67) 14.1 (5.3) NS
6MWD (M) 314.5 (112.8) 357.0 (117.0) 0.005
QOL score 40.7 (25.4) 22.9 (22.3) 0.001
Vascular and Platelet
Baseline AIX (%) 20.3 (8.2) 20.3 (8.1) NS
GTN response [AIX change (%)] 14.1 (10.0) 16.6 (8.1) NS
Salbutamol response [AIX change (%)] 9.9 (10.5) 11.9 (8.3) NS
SNP response (%) 30.5 (21.8) 25.2 (19.7) NS
TXNIP (AU) 144.8 (122.6) 188.5 (126.6) NS
ADMA (μM) 0.66 (0.08) 0.65 (0.09) NS
SDMA (μM) 0.83 (0.28) 0.74 (0.20) 0.013
Biochemistry
Plasma metanephrine (pmol/L) 257.8 (167.2) 239.2 (88.8) NS
Plasma normetanephrine (pmol/L) 918.8 (356.6) 900.7 (295.6) NS
NT-proBNP (ng/L) 1862 (1091–3185) 1469 (774–2841) 0.008
MMP-2 (ng/mL) 217.2 (52.5) 219.8 (49.9) NS
MMP-9 (ng/mL) 27.5 (9.6) 26.5 (10.0) NS
High-sensitivity C-reactive protein (mg/L) 2.4 (1.4–7.1) 3.5 (1.6–11.0) NS
Echocardiographic
LV ejection fraction (%) 31.0 (6) 38 (10) <0.001
LVESV (mL) 136.6 (57.5) 98.9 (52.1) <0.001
SPWD (ms) 119.1 (201.2) 1.74 (141.4) 0.007
IVMD (ms) 43.6 (44.6) 19.9 (33.9) 0.008
6MWD, 6 min walk distance; ADMA, asymmetric dimethyl arginine; AIX, augmentation index; CRT, cardiac resynchronization therapy;
GTN, glycerine trinitrate; IVMD, interventricular mechanical delay; LV, left ventricular; LVESV, left ventricular end-systolic volume; MMP,
matrix metalloproteinase; NS, non-signiﬁcant; NT-proBNP, N terminal proBNP; NYHA, New York Heart Association; QOL, quality of life;
SDMA, symmetric dimethyl arginine; SNP, sodium nitroprusside; SPWD, septal to posterior wall delay; VO2 max, peak oxygen consump-
tion; TXNIP, thioredoxin-interacting protein.
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endothelial function is the possibility that CRT may indeed
have opposing effects on AIX: by increasing stroke volume into
non-compliant vessels with already depressed Windkessel
effect, there would be an increase in the velocity of both the
forward and the reﬂected waves in the peripheral vascula-
ture. It is also possible that extensive pharmacological treat-
ment of our cohort for heart failure and dyslipidemia may
have resulted in pre-CRT improvement of vascular endothe-
lial function. Statins, for instance, are known to cause a
reduction in aortic AIX,
22 Angiotensin-converting enzyme
inhibitors (ACE-I) also signiﬁcantly reduce AIX,
23 and 91% of
our cohort were receiving ACE-I or angiotensin receptor
blocker. It is also possible, given the observation of a (non-
signiﬁcant) 20% improvement on vascular responsiveness
to salbutamol and GTN post-CRT, that a small improvement
in these parameters might have been obscured via type II
error. Indeed, the probability of detecting a change of less
than 0.5 SD of baseline values would have been less than
80%. In the case of responses to salbutamol, for example,
an absolute improvement of less than 5% might have gone
undetected. In addition, the use of β-adrenoceptor antago-
nists would potentially blunt the effect of salbutamol on
AIX, thus obscuring the effect of CRT. Interestingly, the study
cohort included 24% of patients who were not receiving
β-adrenoceptor antagonists presumably because of contra-
indications and/or prior adverse effects. However at base-
line, there was no signiﬁcant difference in AIX response to
salbutamol between patients receiving and not receiving
β-adrenoceptor antagonists.
The lack of effect of CRT on either basal or NO-stimulated
AIX was somewhat different from the results of previous
studies that utilized FMD as a criterion of NO-mediated arte-
rial vasomotion. All of these have shown some evidence of
improvement in FMD. Akar et al.7 observed that although
patients with worse FMD of the brachial artery responded
better to CRT and that these responders had improvement
in FMD at 90 days, the overall improvement was not statisti-
cally signiﬁcant (P = 0.12).
In a subsequent study of 57 patients, Santini et al.8 found
that in a CRT cohort, signiﬁcant improvement in FMD oc-
curred in both responders and non-responders at 3, 6, and
12 months although with somewhat greater improvement
in the responder group than in the non-responder group,
with these results being only of borderline statistical signiﬁ-
cance. A recent study by Warriner et al.9 also found that
lower FMD predicts response to CRT at 12 months. However,
in their cohort, CRT did not result in signiﬁcant improvement
in FMD in either the responder group or the non-responder
group. It is not completely clear to what extent the reported
differential FMD responses in the Santini study represent the
phenomenon of regression to the mean. In any case, we are
unable to make direct comparisons in the current study. We
did not measure FMD, essentially because AIX is a more
reproducible parameter than FMD.24,25 Importantly, in our
study, CRT did not affect ADMA concentrations also indicat-
ing that NO generation via endothelial NO synthase activa-
tion was likely to be unaffected. In one previous study, high
ADMA concentrations tended to predict poor responses to
endothelial NO synthase activation by FMD.26 A further ca-
veat concerning the current ﬁndings is that evaluation of
changes in platelets and blood may not be fully representa-
tive of changes within the myocardium.
It might have been expected that CRT would tend to
normalize patterns of arterial distention and thus decrease
expression of TXNIP given that the latter is shear stress-
dependent.27 However, no change in platelet TXNIP content
occurred. In retrospect, there have been no previous direct
studies of effects of CRT on arterial shear stress, and it may
be that reversal of LV dyssynchrony has minimal effects on
this parameter. Furthermore, platelet TXNIP expression is
suppressed by NO signalling, such as are induced by ACE in-
hibitor therapy.28
A notable exception to the overall negative data in this
study was the observed fall in plasma SDMA concentrations
(Figure 3). This is most unlikely to be a ‘false positive’ given
ﬁrst, the P = 0.013 value. SDMA, unlike ADMA, is only a very
weak inhibitor of NO synthase, but it is a substantial media-
tor of inﬂammatory change.29 This could not be explained
by improved renal function, an important consideration be-
cause SDMA is excreted (mainly) unchanged in the urine.30
A fall in SDMA concentrations independent of alterations
in renal function post-CRT may have reﬂected either
decreased protein catabolism (representing the mechanism
of formation of SDMA via the enzyme, protein arginine
methyltransferase type II). Importantly, although there was
no signiﬁcant ﬂuctuation in other inﬂammatory markers in
the cohort as a whole, patients with a reduction in SDMA
levels also had signiﬁcant reductions in high-sensitivity
C-reactive protein relative to those without a fall in SDMA,
which further supports the concept that amelioration of
inﬂammation activation may occur post-CRT. Interestingly,
a fall in SDMA concentrations also predicted increases in
VO2 max (Figure 3E)
In summary, in an extensively medically treated cohort of
patients, CRT did not signiﬁcantly alter markers of NO signal-
ling. It is therefore unlikely that changes in NO signalling sig-
niﬁcantly contribute to the salutary effects of CRT within
6 months. However, there is some evidence that CRT may
lead to suppression of inﬂammatory activation within the sys-
temic circulation.
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